Clinical trials: Germ Cell Cancer Metastatic
Chemotherapy-induced Nausea and Vomiting
Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma
The purpose of this study is to investigate the effectiveness of intravenous fosaprepitant therapy to reduce nausea and vomiting during the treatment of high dose interleukin-2 (HD IL-2) therapy for metastatic melanoma or…
- Trial name
- HDIL2/Emend (NCT01874119)
- Testing
- Fosaprepitant
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- St. Louis University
Malignant Melanoma
A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma
This open-label, multicenter study will evaluate the pharmacokinetics, safety and efficacy of vemurafenib in Chinese participants with BRAF V600 mutation-positive unresectable or metastatic melanoma.
- Trial name
- NCT01910181
- Testing
- Vemurafenib
- Where
- 2 sites in China
- Volunteers
- 46 people
- Sponsor
- Hoffmann-La Roche
Metastatic Melanoma, Skin Cancer
Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma
Background: Melanoma antigen recognized by T-cells (MART)-1 is a protein present in melanoma cells. An experimental procedure developed for treating patients with melanoma uses the anti-MART-1 F5 gene and a type of virus to make…
- Trial name
- NCT00612222
- Testing
- autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes, ALVAC MART-1 Vaccine, aldesleukin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Mucosal Lentiginous Melanoma, Acral Melanoma
Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
Given the poor prognosis and limited treatment options available for patients with mucosal or acral/lentiginous melanomas who develop metastatic disease, genetic discoveries of KIT mutations in these cancers present the need to…
- Conditions
- Mucosal Lentiginous Melanoma, Acral Melanoma, Melanoma
- Trial name
- NCT00788775
- Testing
- Nilotinib
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Unresectable or Metastatic Melanoma
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
The purpose of this study is to show that Nivolumab and/or Nivolumab in combination with Ipilimumab will extend progression free survival and overall survival compared to Ipilimumab alone.
- Trial name
- NCT01844505
- Testing
- Nivolumab, Ipilimumab
- Where
- 150 sites in United States, Australia and 20 more
- Volunteers
- 945 people
- Sponsor
- Bristol-Myers Squibb
BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC
Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors
This is a phase 1, multicenter, open-label, single-arm study to investigate the safety and tolerability of encorafenib 300 mg once daily (QD) monotherapy in adult Chinese participants with B-RAF Proto-oncogene, Serine/threonine…
- Conditions
- BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC, Melanoma
- Trial name
- OCEANI (NCT05003622)
- Testing
- Encorafenib
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Pierre Fabre Medicament
Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer
Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
This phase II trial is studying how well tanespimycin works in treating patients with inoperable locoregionally advanced or metastatic thyroid cancer.
- Conditions
- Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer, Thyroid Gland Medullary Carcinoma
- Trial name
- NCT00118248
- Testing
- tanespimycin
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Melanoma, Cancer
Phase II Study of Tesetaxel in Metastatic Melanoma
The goal of this clinical research study is to learn if tesetaxel can help to control metastatic melanoma. The safety of this drug will also be studied.
- Trial name
- NCT01064713
- Testing
- Tesetaxel
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer
Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
This phase II trial studies how well giving sunitinib malate works in treating patients with iodine-refractory recurrent or metastatic thyroid cancer.
- Conditions
- Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer, Stage IVB Follicular Thyroid Cancer
- Trial name
- NCT00519896
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Washington
Metastatic Melanoma
Ipilimumab + Temozolomide in Metastatic Melanoma
The goal of this clinical research study is to learn if combining ipilimumab and temozolomide can help to control metastatic melanoma. The safety of this drug combination will be studied.
- Trial name
- NCT01119508
- Testing
- Ipilimumab, Temozolomide
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00788125
- Testing
- carboplatin, dasatinib, etoposide phosphate
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- City of Hope Medical Center
Brain and Central Nervous System Tumors, Cognitive/Functional Effects
Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain
RATIONALE: Donepezil may decrease the side effects caused by radiation therapy to the brain. PURPOSE: This clinical trial is studying how well donepezil works in treating young patients with primary brain tumors previously…
- Conditions
- Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Children, Neurotoxicity
- Trial name
- NCT00452868
- Testing
- Donepezil
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Wake Forest University Health Sciences
Metastatic Uveal Melanoma
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
The purpose of this research is to test if a combination treatment of nivolumab and relatlimab will result in tumor reduction in patients with metastatic uveal melanoma.
- Trial name
- NCT04552223
- Testing
- Nivolumab, Relatlimab
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Jose Lutzky, MD
Metastatic Melanoma
Study of Gene Modified Immune Cells in Patients With Advanced Melanoma
The purpose of this phase 2 study is to find the best way to give this new experimental regimen and determine if it can treat metastatic melanoma in humans.
- Trial name
- F5 (NCT00910650)
- Testing
- F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells, non-myeloablative conditioning chemotherapy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Recurrent Melanoma, Stage IV Melanoma
Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
This clinical trial studies individualized temozolomide (TMZ) in treating patients with stage IV melanoma that cannot be removed by surgery.
- Trial name
- NCT01328535
- Testing
- temozolomide, flow cytometry, staining method
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mayo Clinic
Skin Cancer, Melanoma
Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...
Background: Adoptive cell therapy involves taking white blood cells called lymphocytes from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient to allow the cells to…
- Conditions
- Skin Cancer, Melanoma, Metastatic Melanoma
- Trial name
- NCT01118091
- Testing
- Aldesleukin, CD8 enriched Young TIL
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Cancer, Metastatic Melanoma
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with melanoma that involves taking white blood cells from the patient, growing them in the laboratory in…
- Trial name
- NCT02062359
- Testing
- Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells, Aldesleukin, Cyclophosphamide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Gastrinoma, Glucagonoma
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
This phase II trial studies regorafenib in treating patients with neuroendocrine tumors that have spread from the primary site (place where it started) to other places in the body.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT02259725
- Testing
- regorafenib, laboratory biomarker analysis
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- University of Southern California
Malignant Melanoma
A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma
This open-label single-arm study will evaluate the effect of RO5185426 [RG7204; PLEXXIKON: PLX4032] on the pharmacokinetics of five CYP450 substrates (caffeine, warfarin + vitamin K, omeprazole, dextromethorphan, midazolam)…
- Trial name
- NCT01001299
- Testing
- Drug cocktail, RO5185426
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Hoffmann-La Roche
Melanoma
Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)
The purpose of this study is to determine the safety, tolerability, and objective response rate (ORR) of pembrolizumab (MK-3475) in Chinese participants with locally advanced or metastatic melanoma, with disease progression…
- Trial name
- NCT02821000
- Testing
- Pembrolizumab
- Volunteers
- 103 people
- Sponsor
- Merck Sharp & Dohme LLC